Search Results for "colchicine"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for colchicine. Results 1 to 6 of 6 total matches.
See also: Colcrys
Low-Dose Colchicine for Coronary Artery Disease
The Medical Letter on Drugs and Therapeutics • Apr 05, 2021 (Issue 1621)
Low-Dose Colchicine for Coronary Artery Disease ...
The centuries-old anti-inflammatory drug colchicine
(Colcrys, and others) is FDA-approved for prophylaxis
and treatment of gout flares and for treatment of
familial Mediterranean fever. It is also used off-label
to treat pericarditis, and in recent years has been
investigated for reduction of cardiovascular risk in
patients with coronary artery disease (CAD).
Lodoco: Low-Dose Colchicine for Cardiovascular Event Prevention
The Medical Letter on Drugs and Therapeutics • Oct 02, 2023 (Issue 1686)
Lodoco: Low-Dose Colchicine for Cardiovascular Event Prevention ...
Colchicine (Colcrys, and others), which has been
available in the US for decades for prophylaxis
and treatment of gout flares and other indications
in oral formulations that contain 0.6 mg of the
drug, has now been approved in 0.5-mg tablets as
Lodoco (Agepha) to reduce the risk of myocardial
infarction (MI), stroke, coronary revascularization,
and cardiovascular death in adults with established
atherosclerotic disease or multiple risk factors for
cardiovascular disease.
Med Lett Drugs Ther. 2023 Oct 2;65(1686):156-7 doi:10.58347/tml.2023.1686b | Show Introduction Hide Introduction
Drugs for Gout
The Medical Letter on Drugs and Therapeutics • Oct 30, 2023 (Issue 1688)
with an NSAID,
colchicine, or a systemic corticosteroid. An IL-1 inhibitor can
be used when these drugs ...
Drugs for gout are used to reduce the pain and
inflammation of acute flares, decrease the frequency
of exacerbations, and lower serum urate levels to
prevent recurrent flares, development of tophi, and
joint damage.
Med Lett Drugs Ther. 2023 Oct 30;65(1688):169-75 doi:10.58347/tml.2023.1688a | Show Introduction Hide Introduction
Comparison Table: Some Drugs for Gout (online only)
The Medical Letter on Drugs and Therapeutics • Oct 30, 2023 (Issue 1688)
(colchicine is generally
preferred)
Ibuprofen – generic
200, 400, 600, 800 mg tabs
Acute flare: 800 mg PO ...
View the Comparison Table: Some Drugs for Gout
Med Lett Drugs Ther. 2023 Oct 30;65(1688):e176-9 doi:10.58347/tml.2023.1688c | Show Introduction Hide Introduction
Rilonacept (Arcalyst) for Recurrent Pericarditis
The Medical Letter on Drugs and Therapeutics • Sep 06, 2021 (Issue 1632)
— The standard first-line
treatment for recurrent pericarditis in most patients
is colchicine plus ...
Rilonacept (Arcalyst – Kiniksa), an interleukin-1 (IL-1)
antagonist that has been available for years for
treatment of cryopyrin-associated periodic syndromes,
has now been approved by the FDA for treatment
of recurrent pericarditis and prevention of further
recurrences in patients ≥12 years old. It is the first drug
to be approved in the US for this indication. Anakinra
(Kineret), an IL-1 receptor antagonist FDA-approved for
treatment of rheumatoid arthritis, has been used off-label
for years for treatment of recurrent pericarditis.
Two Vonoprazan Combinations (Voquezna) for H. pylori
The Medical Letter on Drugs and Therapeutics • Oct 31, 2022 (Issue 1662)
in
patients with renal impairment
Colchicine
Clarithromycin can increase concentrations of colchicine ...
The FDA has approved vonoprazan, a potassium-competitive
acid blocker, copackaged with amoxicillin
(Voquezna Dual Pak – Phathom) and with amoxicillin
and clarithromycin (Voquezna Triple Pak) for
treatment of Helicobacter pylori infection in adults.
Vonoprazan is the first potassium-competitive acid
blocker to be approved in the US. It has been available
in Japan for treatment of various acid-related
disorders since 2014. Vonoprazan is not available
alone in the US.